Advertisement

Topics

Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene

02:51 EDT 11 Jul 2018 | ChinaBio Today

Tasly Biopharma paid $48 million in stock to buy out its China JV partner Transgene (P: TNG), which holds China rights to two Transgene products: T601, an oncolytic virus, and T101, a therapeutic vaccine. The stock represents 2.53% of Tasly Biopharma's capital after a pre-IPO investment round, which priced at the same time as the Transgene transaction. Tasly Biopharma, the novel drug subsidiary of Tasly Pharma, has announced plans to conduct a Hong Kong IPO. The Transgene deal values the Tasly Biopharma at $1.9 billion. More details....

Stock Symbol: (SHA: 600535)

Share this with colleagues:

Original Article: Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene

NEXT ARTICLE

More From BioPortfolio on "Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...